A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
Authors
Keywords
-
Journal
Journal of Translational Medicine
Volume 9, Issue 1, Pages 204
Publisher
Springer Nature
Online
2011-11-30
DOI
10.1186/1479-5876-9-204
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Markers of Response to Treatment for Melanoma
- (2011) Mario Sznol CANCER JOURNAL
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
- (2011) C. Garbe et al. ONCOLOGIST
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma
- (2010) A. A. Sarnaik et al. CLINICAL CANCER RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti–CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy
- (2010) Margaret K. Callahan et al. SEMINARS IN ONCOLOGY
- Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms
- (2009) Enrico Ruffini et al. ANNALS OF THORACIC SURGERY
- Ipilimumab: controversies in its development, utility and autoimmune adverse events
- (2009) Jeffrey Weber CANCER IMMUNOLOGY IMMUNOTHERAPY
- Induction of indoleamine 2, 3-dioxygenase by death receptor activation contributes to apoptosis of melanoma cells via mitochondrial damage-dependent ROS accumulation
- (2009) Turgut Cetindere et al. CELLULAR SIGNALLING
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck
- (2009) Jan Boucek et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Predictive Biomarkers: Identification and Verification
- (2009) Timothy J. Yeatman JOURNAL OF CLINICAL ONCOLOGY
- Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
- (2009) Willemijn B. Breunis et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Clinical significance of tumor-infiltrating lymphocytes in neoplastic progression and lymph node metastasis of human breast cancer
- (2008) Bor-Ching Sheu et al. BREAST
- Prognostic implications of type and density of tumour-infiltrating lymphocytes in gastric cancer
- (2008) H E Lee et al. BRITISH JOURNAL OF CANCER
- CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab?
- (2008) C. Menard et al. CLINICAL CANCER RESEARCH
- Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-Dioxygenase in Patients with Melanoma Undergoing CTLA4 Blockade
- (2008) A. Ribas et al. CLINICAL CANCER RESEARCH
- Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
- (2008) Lawrence Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Response to Imatinib Mesylate in KIT-Mutated Melanoma
- (2008) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma
- (2008) Maria Christina Cox et al. LEUKEMIA & LYMPHOMA
- Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type and BRCA1 loss
- (2008) Blaise Clarke et al. MODERN PATHOLOGY
- Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase
- (2008) A. J. Muller et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Absolute lymphocyte count is a novel prognostic indicator in ALL and AML
- (2007) Guillermo De Angulo et al. CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started